STM publisher Elsevier has announced the launch of a new module in PharmaPendium, its fully searchable database of drug approval documents and extracted data to inform critical drug development decisions. The PharmaPendium Efficacy Module features over 1.4 million extracted efficacy observations from FDA and EMA drug approval packages, providing insights to researchers to support clinical development decisions and clinical trial design.
The failure rates for Phase I and Phase II clinical trials range from 35% to 57%; a lack of efficacy is one of the most common reasons for continued late-stage trial failures, followed by a lack of drug safety. The data in the PharmaPendium Efficacy Module helps researchers to improve translational research (from animal to human) which enables researchers to predict human outcomes with greater confidence, resulting in more informed clinical trial study designs.
The PharmaPendium Efficacy Module helps researchers quickly find relevant comparative information by enabling them to search on an indication and/or endpoint of interest. It features the most in-depth efficacy database on FDA and EMA approved drugs, where information such as indication tested, sample size, primary or secondary endpoints, study design, and age groups, can be easily searched and filtered on to get critical insights which can improve clinical trial design and mitigate the risk of clinical failure.
Brought to you by Scope e-Knowledge Center, a world-leading provider of abstraction, indexing, entity extraction and knowledge organisation models (Taxonomies, Thesauri and Ontologies).
